MX2022006308A - Derivados de carbazol polimorfos y usos de los mismos. - Google Patents
Derivados de carbazol polimorfos y usos de los mismos.Info
- Publication number
- MX2022006308A MX2022006308A MX2022006308A MX2022006308A MX2022006308A MX 2022006308 A MX2022006308 A MX 2022006308A MX 2022006308 A MX2022006308 A MX 2022006308A MX 2022006308 A MX2022006308 A MX 2022006308A MX 2022006308 A MX2022006308 A MX 2022006308A
- Authority
- MX
- Mexico
- Prior art keywords
- polymorphic
- carbazole derivatives
- ahr
- involved
- compositions
- Prior art date
Links
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 title 1
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 abstract 3
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 239000012458 free base Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940481P | 2019-11-26 | 2019-11-26 | |
| PCT/US2020/062197 WO2021108528A1 (en) | 2019-11-26 | 2020-11-25 | Polymorphic carbazole derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006308A true MX2022006308A (es) | 2022-06-22 |
Family
ID=73856339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006308A MX2022006308A (es) | 2019-11-26 | 2020-11-25 | Derivados de carbazol polimorfos y usos de los mismos. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11591339B2 (https=) |
| EP (2) | EP4065582B1 (https=) |
| JP (2) | JP2023502531A (https=) |
| KR (1) | KR20220125231A (https=) |
| CN (1) | CN115279764B (https=) |
| AU (1) | AU2020394424A1 (https=) |
| CA (1) | CA3159317A1 (https=) |
| ES (1) | ES3028099T3 (https=) |
| FI (1) | FI4065582T3 (https=) |
| IL (1) | IL293326A (https=) |
| MX (1) | MX2022006308A (https=) |
| PL (1) | PL4065582T3 (https=) |
| PT (1) | PT4065582T (https=) |
| WO (1) | WO2021108528A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| AU2020394424A1 (en) | 2019-11-26 | 2022-06-16 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| US12570638B2 (en) | 2020-05-20 | 2026-03-10 | Sail Biomedicines, Inc. | Fused imidazole derivatives as AHR antagonists |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3274118A (en) | 1962-01-22 | 1966-09-20 | Lithium Corp | Preparation of stable non-pyrophoric organometallic compositions |
| US5721356A (en) | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
| US5962473A (en) | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| EP1343506A1 (de) | 2000-12-19 | 2003-09-17 | MERCK PATENT GmbH | Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate |
| EP2168576A3 (en) | 2001-09-14 | 2010-05-26 | Shionogi & Co., Ltd. | Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases |
| ES2285164T3 (es) | 2002-09-04 | 2007-11-16 | Schering Corporation | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina. |
| MY133311A (en) | 2002-09-19 | 2007-11-30 | Schering Corp | Novel imidazopyridines as cyclin dependent kinase inhibitors |
| JP4895806B2 (ja) | 2003-04-09 | 2012-03-14 | エクセリクシス， インク． | Ｔｉｅ−２モジュレータと使用方法 |
| AR047969A1 (es) | 2004-02-25 | 2006-03-15 | Schering Corp | Pirazolotriazinas como inhibidores de quinasa |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| JP2008520749A (ja) | 2004-11-23 | 2008-06-19 | レディ ユーエス セラピューティックス， インコーポレイテッド | 新規二環式ヘテロ環化合物、その調製のためのプロセス、およびその新規二環式ヘテロ環化合物を含む組成物 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008058126A2 (en) | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| JP5643105B2 (ja) | 2007-12-14 | 2014-12-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規イミダゾ［１，２−ａ］ピリジン及びイミダゾ［１，２−ｂ］ピリダジン誘導体 |
| WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| JP5802676B2 (ja) | 2009-12-04 | 2015-10-28 | センワ バイオサイエンシズ インコーポレイテッド | Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物 |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| WO2012044562A2 (en) | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine pde10 inhibitors |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| AP2013007253A0 (en) | 2011-04-21 | 2013-11-30 | Origenis Gmbh | Pyrazolo [4,3-D] pyrimidines useful as kinase inhibitors |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| EP2788476B1 (en) | 2011-12-08 | 2019-05-22 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| AR090650A1 (es) | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014060112A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| WO2014138485A1 (en) | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| MX388871B (es) * | 2014-06-27 | 2025-03-20 | Nogra Pharma Ltd | Moduladores del receptor arilo y metodos para elaborar y usar los mismos. |
| CN108290855A (zh) | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途 |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| TW201841916A (zh) | 2017-04-12 | 2018-12-01 | 美商麥珍塔治療學股份有限公司 | 芳香烴受體拮抗劑及其用途 |
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| EP3867253A4 (en) | 2018-10-16 | 2022-05-18 | Ikena Oncology, Inc. | Indole ahr inhibitors and uses thereof |
| AU2020394424A1 (en) | 2019-11-26 | 2022-06-16 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| EP4065090A1 (en) | 2019-11-26 | 2022-10-05 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
| CA3167283A1 (en) | 2020-01-10 | 2021-07-15 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
| MX2023004847A (es) | 2020-10-28 | 2023-07-11 | Ikena Oncology Inc | Combinación de un inhibidor del receptor de hidrocarburos de arilo (ahr) con un inhibidor de pdx o doxorrubicina. |
-
2020
- 2020-11-25 AU AU2020394424A patent/AU2020394424A1/en not_active Abandoned
- 2020-11-25 WO PCT/US2020/062197 patent/WO2021108528A1/en not_active Ceased
- 2020-11-25 EP EP20828454.7A patent/EP4065582B1/en active Active
- 2020-11-25 PT PT208284547T patent/PT4065582T/pt unknown
- 2020-11-25 EP EP25158597.2A patent/EP4529955A3/en active Pending
- 2020-11-25 MX MX2022006308A patent/MX2022006308A/es unknown
- 2020-11-25 KR KR1020227021719A patent/KR20220125231A/ko active Pending
- 2020-11-25 JP JP2022530741A patent/JP2023502531A/ja active Pending
- 2020-11-25 CA CA3159317A patent/CA3159317A1/en active Pending
- 2020-11-25 ES ES20828454T patent/ES3028099T3/es active Active
- 2020-11-25 IL IL293326A patent/IL293326A/en unknown
- 2020-11-25 US US17/104,237 patent/US11591339B2/en active Active
- 2020-11-25 CN CN202080092193.1A patent/CN115279764B/zh active Active
- 2020-11-25 FI FIEP20828454.7T patent/FI4065582T3/fi active
- 2020-11-25 PL PL20828454.7T patent/PL4065582T3/pl unknown
-
2023
- 2023-01-19 US US18/156,562 patent/US12162884B2/en active Active
-
2024
- 2024-10-21 US US18/921,463 patent/US20250276975A1/en active Pending
-
2025
- 2025-05-20 JP JP2025084133A patent/JP2025113368A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021108528A1 (en) | 2021-06-03 |
| PL4065582T3 (pl) | 2025-08-18 |
| JP2025113368A (ja) | 2025-08-01 |
| US20230286990A1 (en) | 2023-09-14 |
| US20250276975A1 (en) | 2025-09-04 |
| CN115279764B (zh) | 2026-04-07 |
| EP4529955A3 (en) | 2025-07-16 |
| US12162884B2 (en) | 2024-12-10 |
| EP4065582B1 (en) | 2025-02-19 |
| KR20220125231A (ko) | 2022-09-14 |
| EP4065582A1 (en) | 2022-10-05 |
| FI4065582T3 (fi) | 2025-05-25 |
| US11591339B2 (en) | 2023-02-28 |
| AU2020394424A1 (en) | 2022-06-16 |
| EP4529955A2 (en) | 2025-04-02 |
| CN115279764A (zh) | 2022-11-01 |
| PT4065582T (pt) | 2025-05-22 |
| JP2023502531A (ja) | 2023-01-24 |
| IL293326A (en) | 2022-07-01 |
| CA3159317A1 (en) | 2021-06-03 |
| ES3028099T3 (en) | 2025-06-18 |
| US20210253579A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019011693A (es) | Compuestos que inhiben la proteina mcl-1. | |
| ECSP24026455A (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| NI201900013A (es) | Inhibidor de piridopirimidinona cdk2/4/6 | |
| CL2020001546A1 (es) | Compuestos de 4-azaindol. | |
| ECSP20060827A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b | |
| CL2019003015A1 (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
| CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
| UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
| MX2017012558A (es) | Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para su uso. | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| CU20180152A7 (es) | Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| CL2022000093A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas | |
| CU20180006A7 (es) | Compuestos de indazaol y azaindazol como inhibidores de irak-4 | |
| CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
| CO2018006164A2 (es) | Compuestos útiles como inhibidores de cinasa | |
| CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
| CO2021001219A2 (es) | Benzimidazoles sustituidos como inhibidores de pad4 | |
| MX2022006308A (es) | Derivados de carbazol polimorfos y usos de los mismos. | |
| CL2020001107A1 (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
| CU24550B1 (es) | Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos | |
| MX2019003310A (es) | Inhibidores de dopamina-b-hidroxilasa. | |
| MX2016010524A (es) | Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico. |